Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
Susanne Saußele(University of Mannheim), Rüdiger Hehlmann(Heidelberg University), Dietrich W. Beelen(Essen University Hospital), Claudia Haferlach(Munich Leukemia Laboratory (Germany)), Brigitte Schlegelberger(Heidelberg University), Ernst Holler(University Hospital Regensburg), Andreas Hochhaus(Jena University Hospital), Nadine Pletsch(Universität Hamburg), Christiane Falge(Nuremberg Hospital), Robert Dengler(Praxis), Hans‐Jochem Kolb(Deutsche Klinik für Diagnostik), Markus Pfirrmann(Ludwig-Maximilians-Universität München), Anthony D. Ho(Heidelberg University), Michael Lauseker(Zimmer Biomet (Germany)), Armin Leitner(Universität Hamburg), Aloïs Gratwohl, Günter Schlimok(University Hospital Augsburg), Joerg Hasford(Ludwig-Maximilians-Universität München), Martin C. Müller(Universität Hamburg), Susanne Schnittger(Goethe University Frankfurt), Lothar Kanz(University of Freiburg), Axel R. Zander(Max Zeller Söhne (Switzerland)), Renate Arnold(Charité - Universitätsmedizin Berlin), Donald Bunjes(University Hospital Ulm), Rainer Schwerdtfeger(Deutsche Klinik für Diagnostik)
Cited by 220
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k